2 weeks Ago By Defense World Staff
Bank of Montreal Can bought a new position in shares of Maravai LifeSciences Holdings, Inc. ( NASDAQ:MRVI – Free Report ) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 77,679 shares of the company’s stock, valued at approximately $423,000.
Several other institutional investors and hedge funds also recently modified their holdings of the business. Wells Fargo & Company MN raised its position in shares of Maravai LifeSciences by 39.8% during the 4th quarter.
Wells Fargo & Company MN now owns 52,685 shares of the company’s stock worth $287,000 after purchasing an additional 15,001 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its position in shares of Maravai LifeSciences by 29.
5% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,664,210 shares of the company’s stock valued at $25,420,000 after acquiring an additional 1,062,485 shares in the last quarter.
Geode Capital Management LLC boosted its stake in shares of Maravai LifeSciences by 1.6% during the fourth quarter. Geode Capital Management LLC now owns 2,794,961 shares of the company’s stock valued at $15,236,000 after acquiring an additional 42,884 shares during the last quarter.
JPMorgan Chase & Co. increased its position in Maravai LifeSciences by 4.9% during the 4th quarter.
JPMorgan Chase & Co. now owns 4,250,656 shares of the company’s stock worth $23,166,000 after purchasing an additional 200,411 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co.
Ltd. raised its stake in Maravai LifeSciences by 118.5% in the 4th quarter.
Mitsubishi UFJ Asset Management Co. Ltd. now owns 52,508 shares of the company’s stock valued at $298,000 after purchasing an additional 28,480 shares during the last quarter.
Hedge funds and other institutional investors own 50.25% of the company’s stock. Analyst Ratings Changes MRVI has been the subject of a number of recent research reports.
Baird R W downgraded shares of Maravai LifeSciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 26th. Stifel Nicolaus set a $5.00 price objective on Maravai LifeSciences in a report on Friday, March 21st.
Bank of America reduced their target price on Maravai LifeSciences from $9.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, March 3rd.
Morgan Stanley lowered their price target on Maravai LifeSciences from $7.00 to $5.00 and set an “equal weight” rating for the company in a report on Tuesday, March 25th.
Finally, Robert W. Baird lowered shares of Maravai LifeSciences from an “outperform” rating to a “neutral” rating and cut their price objective for the stock from $9.00 to $3.
00 in a report on Wednesday, February 26th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the company. According to MarketBeat.
com, Maravai LifeSciences has a consensus rating of “Hold” and a consensus price target of $6.34. Maravai LifeSciences Trading Up 9.
0 % Shares of MRVI stock opened at $1.93 on Wednesday. The company has a quick ratio of 9.
94, a current ratio of 10.74 and a debt-to-equity ratio of 0.89.
Maravai LifeSciences Holdings, Inc. has a fifty-two week low of $1.67 and a fifty-two week high of $11.
56. The firm’s 50 day moving average price is $2.58 and its two-hundred day moving average price is $4.
74. The stock has a market cap of $490.87 million, a price-to-earnings ratio of -1.
18 and a beta of 0.18. Insider Activity In other news, General Counsel Kurt Oreshack sold 25,000 shares of the stock in a transaction dated Friday, January 31st.
The stock was sold at an average price of $5.03, for a total value of $125,750.00.
Following the completion of the sale, the general counsel now owns 167,618 shares in the company, valued at approximately $843,118.54. This trade represents a 12.
98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link . Insiders own 0.
63% of the company’s stock. Maravai LifeSciences Profile ( Free Report ) Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Further Reading Five stocks we like better than Maravai LifeSciences Trading Halts Explained How to Invest in Micro-Cap Stocks Like a Pro Manufacturing Stocks Investing Investors Sell Microsoft Stock on OpenAI News—Time to Buy? How to Read Stock Charts for Beginners Take-Two Interactive: A Defensive Play Set to Explode Want to see what other hedge funds are holding MRVI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maravai LifeSciences Holdings, Inc. ( NASDAQ:MRVI – Free Report ).
Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter ..
